Competition is heating up in the FGF21 analog class for non-alcoholic steatohepatitis, with Akero Therapeutics, Inc. preparing to initiate an adaptive Phase IIb/III study of its drug efruxifermin (EFX/AKR-001), which it says could provide a relatively quick path to producing pivotal data and give it a boost as the NASH space resettles after this year’s clinical development setbacks for Intercept Pharmaceuticals, Inc. and Genfit SA.
Leadership in the NASH space generally is seen as wide open again after Genfit’s Phase III failure in May with PPAR agonist elafibranor and Intercept’s complete response letter from the US Food and Drug Administration for FXR agonist obeticholic acid (OCA) on 29 June. (Also see "RESOLVE-IT Failure Dashes Genfit's NASH Hopes" - Scrip, 12 May, 2020
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?